Recently, Sinocare made its presence at both the 50th Arab Health and Medlab Middle East 2025 in Dubai, showcasing the strength of Chinese innovation on the global healthcare technology stage.

Driven by both the UAE’s "Vision 2021" and China’s "Belt and Road" initiative, the Middle East has become a key strategic region for Chinese companies expanding their overseas markets. Sinocare has strategically seized this opportunity, deeply integrating its global expansion with digital and intelligent innovation, displaying outstanding technological strength and forward-thinking vision at the Dubai exhibitions.

At the event, Sinocare showcased four core product lines in full display: the Personal Palm Lab (PPL), Precision Desk Lab (PDL), Precision Wearable Systems (PWS), and the Digital Diabetes Management Solution. Together, these products build a comprehensive, full-cycle health management system that provides users with all-encompassing, personalized health services.

BGM: Precision Blood Glucose at Your Fingertips

Sinocare’s series of blood glucose meters, including Safe AQ Smart, Safe AQ UG (Dual-function Blood Glucose and Uric Acid Meter), and Safe-Accu, offer the standout advantages of accuracy, simplicity, and affordability. With just a drop of blood, users can accurately measure their blood glucose levels, making them the first choice for daily monitoring among diabetes patients.

At the same time, Sinocare is actively advancing the research and application of multi-parameter testing. In response to chronic diseases such as high uric acid, hypertension, and hyperlipidemia, Sinocare has developed a series of diagnostic products and related specialized services, offering more comprehensive and scientifically based health management solutions.

CGM: No Finger Prick, Continuous Glucose Monitoring for 15 Days

Notably, during the exhibition, Sinocare showcased the latest model of its iCAN Continuous Glucose Monitoring (CGM) system for the first time. This system employs third-generation glucose sensor preparation technology, using an implantable sensor to continuously monitor glucose concentrations in interstitial fluid. With the assistance of smart algorithms, the data is converted into an intuitive blood glucose fluctuation curve. Continuous monitoring for 15 days provides a comprehensive and accurate reflection of how a patient’s blood glucose levels change in response to factors such as diet, medication, exercise, and treatment plans. This data provides a scientific basis for doctors to formulate personalized treatment plans, helping patients achieve more efficient blood glucose management.

iCARE-1300: More Accurate with Liquid-phase Single Sample

For a long time, primary medical institutions have faced challenges such as limited resources and a shortage of staff, which severely restricted their ability to improve diagnostic capabilities. The Sinocare iCARE-1300 (portable fully automated multifunctional analyzer) offers a breakthrough solution to this dilemma.

The device uses liquid-phase single sample technology, innovatively integrating three major testing modules—five-part blood cell analysis, liquid-phase biochemistry, and immunology—into one unit. It enables the rapid and accurate detection of nearly 100 testing parameters. This one device functions as a complete "desktop laboratory," significantly enhancing the diagnostic capacity of grassroots medical institutions and providing patients with more convenient and efficient healthcare services. This innovative solution is playing a key role in elevating the overall level of grassroots medical care.

At this year's Dubai medical exhibitions, Sinocare not only shone with its innovation and strength but also demonstrated its firm commitment to implementing a global development strategy. Moving forward, Sinocare will continue to increase its investment in medical technology innovation, explore cutting-edge technologies, expand application scenarios, and contribute more wisdom and strength to the health of global users, leading digital health management to new heights.